Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2021 | MERKLIN 1: domatinostat + avelumab in MCC

Paolo Ascierto • 18 Sep 2021
ESMO 2021
Merkel Cell Carcinoma Skin Cancer Antibodies Avelumab Domatinostat
MERKLIN 1

Paolo A. Ascierto, MD, National Tumor Institute, Milan, Italy, explains the rationale of the MERKLIN 1 trial (NCT04874831), which investigates the efficacy of a histone deacetylase inhibitor, domatinostat, in combination with a PD-1 inhibitor, avelumab in patients with treatment-naïve metastatic Merkel cell carcinoma (MCC). This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.

More from Paolo Ascierto

2:03
7-y results from CheckMate 238: adjuvant NIVO vs IPI in resected stage III/IV melanoma
Paolo Ascierto • 21 Oct 2023
2:03
7-year results from CheckMate 238: adjuvant nivolumab in melanoma
Paolo Ascierto • 21 Oct 2023
2:38
Updates in melanoma at ESMO 2022
Paolo Ascierto • 12 Sep 2022
2:14
Standard-of-care and future research directions for advanced squamous cell carcinoma
Paolo Ascierto • 12 Sep 2022

Related Videos

1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
2:12
Novel immunotherapeutic approaches to treat patients with melanoma
Christoffer Gebhardt • 9 Apr 2024
1:22
INTerpath-001: individualized neoantigen vaccines with pembrolizumab in melanoma
Christoffer Gebhardt • 9 Apr 2024
2:15
Reducing the need for sentinel node biopsies in cutaneous melanoma
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals